FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to	ST
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Moorin Jay					2. Issuer Name <b>and</b> Ticker or Trading Symbol  EAGLE PHARMACEUTICALS, INC. [ EGRX ]							(Ch	telationship ( eck all applic X Directo	cable) or	g Pers	10% Ov	ner	
	QUEST IN	IVESTMENTS,			3. Date of Earliest Transaction (Month/Day/Year) 04/21/2015								officer below)	(give title		Other (s below)	pecify	
2430 VANDERBILT BEACH ROAD, 108-190  (Street)  NAPLES FL 34109					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)										Form f Persor		e than	One Repoi	ting	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Code (Instr. 5)				5. Amou Securitie Beneficia Owned F	s ally following	Form (D) o	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
							Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) if any of (Month/Day/Year) ative		ate, Tr	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$59.31	04/21/2015			A		10,000		(1)	04/20/2025	Common Stock	10,000	\$0.00	10,000	0	D		

## **Explanation of Responses:**

1. The option fully vests on April 21, 2016, subject to the reporting person's continuous service with the issuer as of the vesting date.

## Remarks:

/s/ Scott Tarriff, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person

Date

04/22/2015

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.